A second pivotal phase III trial of trabectedin in the US in patients with relapsed ovarian cancer.
Latest Information Update: 29 Dec 2011
Price :
$35 *
At a glance
- Drugs Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- 29 Dec 2011 New trial record